Liraglutide group
Liraglutide was injected subcutaneously once daily into the abdomen, thigh, or upper arm. It was commenced at a starting dose of 0.6 mg once per day. The dose was increased to 1.2 mg/day after 1 week and 1.8 mg/day after the second week. Those who did not tolerate the increased dose continued to maintain the original dose of 0.6 mg/day or 1.2 mg/day. If the drug was tolerated, the patient was required to maintain the maximum tolerated dose. All adjustments occurred under the guidance of the research team. Patients continued CPAP treatment during this period.